论文部分内容阅读
目的 :研究不同的化疗方法治疗晚期非小细胞肺癌 (NSCLC)并观察其疗效和毒副反应。方法 :将 5 5例晚期NSCLC患者分 4组 ,A组经皮肺穿刺瘤体内注射卡铂 (PCI) +支气管动脉灌注 (BAI)双途径化疗 13例 ,B组PCI+VP 16静滴 12例 ,C组单纯BAI 18例 ,D组传统静脉化疗 12例进行临床对比观察。结果 :近期有效率A组为76 .9% ,B组为 5 8%高于C组 33.3% ,明显高于D组的 16 .7% (P <0 .0 1)。一年生存率A组 6 9.2 % ,B组 75 % ,优于C组的 38.9% ,更明显优于D组 8.3% (P <0 .0 1)。一般状况的改善A、B、C三组明显优于D组 (P <0 .0 1) ;而毒副反应均明显低于D组 (P <0 .0 1)。结论 :PCI是一种安全、简便的直接介入疗法 ,联合BAI或VP 16静滴双途径化疗是晚期NSCLC较为理想有效的综合性治疗手段 ,且PCI+VP 16疗法较PCI+BAI疗法更安全、简便、费用少 ,并发症少。
Objective: To study different chemotherapy methods for the treatment of advanced non-small cell lung cancer (NSCLC) and observe its efficacy and toxicity. METHODS: Fifty-five patients with advanced NSCLC were divided into 4 groups. In group A, percutaneous injection of carboplatin (PCI) + bronchial arterial infusion (BAI) was performed in 13 patients in Group B percutaneous transthoracic puncture, and in group B (PCI + VP 16) in group B; There were 18 cases of BAI in group C and 12 cases of traditional venous chemotherapy in group D. Results: The effective rate in the recent A group was 76.9%, and the B group was 58% higher than the C group 33.3%, which was significantly higher than the D group’s 16.7% (P < 0.01). The one-year survival rate was 6 9.2% in group A and 75% in group B, which was better than 38.9% in group C, which was significantly better than that in group D (8.3%, P < 0.01). Improvements in general conditions were significantly better in group A, B, and C than in group D (P < 0.01), and adverse toxicities were significantly lower than in group D (P <0.01). Conclusion: PCI is a safe and simple direct interventional therapy, combined with BAI or VP 16 intravenous infusion chemotherapy is an ideal and effective comprehensive treatment for advanced NSCLC, and PCI+VP 16 is safer than PCI+BAI. Simple, cost-effective and less complications.